Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Monday, February 19, 2018
 
Recommended for you
In Race for Blood Cancer Therapy, a Chinese Biotech Firm Surges 500%
Bloomberg
Trump Budget Touts Lower Drug Prices, But No Medicare Negotiation
Xconomy • Alex Lash
Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition?
Seeking Alpha • Biosci Capital Partners
Lupin launches generic influenza treatment capsules in the US
The Economic Times of India • Pti
GDS Investments' 2017 Year-End Letter
Seeking Alpha • Gds Investments
D.C. Week: Congress Passes Spending Bill
MedPage Today • Shannon Firth
Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist
Seeking Alpha • Giesbers Investment Strategy
The Health 202: Republicans kill Obamacare's controversial "death panel"
Washington Post • Paige Winfield Cunningham
Beyond Tamiflu: After Decades With Just One Main Drug To Fight Virus, More May Be On The Horizon
Kaiser Health News
New Drugs Are Coming to Fight Nasty Flu Seasons
Bloomberg
 
Recommended for You
Biotechnology, Cancer
In Race for Blood Cancer Therapy, a Chinese Biotech Firm Surges 500%
Bloomberg
GenScript has surged since June report of positive data CEO says go-ahead for human trials likely in second quarter In the global race to use human immune cells to fight cancers, a little-known Chinese firm called GenScript Biotech Corp. is emerging as...
Share
Gilead Sciences, Health Policy
Trump Budget Touts Lower Drug Prices, But No Medicare Negotiation
XconomyAlex Lash
National — As president-elect, Donald Trump in January 2017 slammed drug companies for “getting away with murder” and said he supported Medicare negotiation. He vowed during last month’s State of the Union speech that drug prices “will come down.” Today, his administration’s...
Share
Gilead Sciences, Health Finance
Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition?
Seeking AlphaBiosci Capital Partners
Summary Gilead Sciences recently disclosed that the company is in discussion to potentially acquire a gene-editing company. Bill Lundberg, M.D., recently stepped down as chief scientific officer to serve as senior advisor (and is replaced by Dr. Tony Ho). Dr. Ho is...
Share
Gilead Sciences
Lupin launches generic influenza treatment capsules in the US
The Economic Times of IndiaPti
Drug firm Lupin today said it has launched in the US market its generic Oseltamivir Phosphate capsules, used for treatment of influenza. The company said in a BSE filing that it has launched the new tablets after receiving approval from the United...
Share
Economic Policy, Electric Vehicles
GDS Investments' 2017 Year-End Letter
Seeking AlphaGds Investments
Summary Value will outperform growth over the next 3-5 years. Broad-based stock indices will struggle over the next 3 to 5 years. Bonds are in the early stages of a long-term bear market. He that can have patience can have what he...
Share
Barack Obama, Gilead Sciences
D.C. Week: Congress Passes Spending Bill
MedPage TodayShannon Firth
WASHINGTON -- Just before dawn on Friday, Congress passed another short-term spending bill that addresses several significant healthcare issues, such as the opioid crisis and keeping community health centers running, and it keeps the government open until late March. Congress Passes Short-Term...
Share
Disney Channel, Gilead Sciences
Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist
Seeking AlphaGiesbers Investment Strategy
Summary Seems that I started the future-proof portfolio for young investors just before a market dip. Measured in my home currency euro, the portfolio is currently down 8 percent. On the bright side, there already were some nice dividend increases and, sadly,...
Share
Elections & Polls, Gilead Sciences
The Health 202: Republicans kill Obamacare's controversial "death panel"
Washington PostPaige Winfield Cunningham
You are reading The Health 202, our must-read newsletter on health policy. Not a regular subscriber? SIGN UP NOW AHH, OOF and OUCH TRUMP TEMPERATURE AGENCY ALERT MEDICAL MISSIVES Speaking of Science Five major psychiatric diseases have overlapping patterns of genetic activity,...
Share
Gilead Sciences, Health Reform
Beyond Tamiflu: After Decades With Just One Main Drug To Fight Virus, More May Be On The Horizon
Kaiser Health News
“For several decades now, we have not sought to develop the tools we need to fight the flu,” said Olga Jonas, a senior fellow at the Harvard Global Health Institute. “The tax we pay for this folly is as inexorable as it...
Share
Gilead Sciences, GlaxoSmithKline plc
New Drugs Are Coming to Fight Nasty Flu Seasons
Bloomberg
Shionogi, Roche prepare to sell new anti-flu drug this year More alternatives seen boosting market to $1.2 billion by 2025 Flu has been on a vicious march this winter, evading vaccines, overwhelming hospitals and prompting school closures from California to Hong Kong...
Share